Çocuk Sağlığı ve Hastalıkları Dergisi
2014 , Vol 57 , Num 2
The use of risperidon in prepubertal children
Dr. Sami Ulus Kadın Doğum, Çocuk Sağlığı ve Hastalıkları Eğitim ve Araştırma Hastanesi 1Çocuk ve Ergen Ruh Sağlığı
ve Hastalıkları Uzmanı, Hacettepe Üniversitesi Tıp Fakültesi 2Çocuk ve Ergen Ruh Sağlığı ve Hastalıkları Doçenti
*İletişim: ecengel@hacettepe.edu.tr
The pharmacokinetics and pharmacodynamics of antipsychotics and their
effect on pubertal development have not been clarified. However, their use
has increased in prepubertal children. In this study, the pharmacokinetics,
efficacy and side effects of risperidone, which is the most commonly used
second-generation antipsychotic in pre-adolescence, were reviewed. PubMed
and Google Scholar were scanned using the key words “risperidone, prepubescent,
pre-school, younger age”. Studies that did not discriminate for age
range and those written in a language other than English or Turkish were
excluded. Risperidone has a shorter half-life in prepuberty. It was observed
that although risperidone has been approved only for autism, it has been
frequently used off-label to treat irritability and aggression associated with
developmental disorders, and despite its low evidence level, it was found
effective and well tolerated. In most of the studies, prepubertal children were
not evaluated separately. It is impossible to foresee the effects of risperidone
on the progress of the developmental disorders and the long-term side effects,
so the risk/benefit ratio should be well considered, especially for prepubertal
off-label usage.
Anahtar Kelimeler :
risperidon, ergenlik öncesi, okul öncesi, küçük yaş.